Acticor Biotech SAS
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Pha… Read more
Acticor Biotech SAS (ALACT) - Total Liabilities
Latest total liabilities as of June 2024: €15.51 Million EUR
Based on the latest financial reports, Acticor Biotech SAS (ALACT) has total liabilities worth €15.51 Million EUR as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Acticor Biotech SAS - Total Liabilities Trend (2007–2023)
This chart illustrates how Acticor Biotech SAS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Acticor Biotech SAS Competitors by Total Liabilities
The table below lists competitors of Acticor Biotech SAS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
2F5
F:2F5
|
Germany | €3.98 Million |
|
Star Vault AB (publ)
PINK:SRVTF
|
USA | $849.62K |
|
TVD Holdings PCL
BK:TVDH
|
Thailand | ฿626.42 Million |
|
Aruma Resources Ltd
AU:AAJ
|
Australia | AU$128.20K |
|
Visionary Gold Corp
PINK:VIZNF
|
USA | $847.41K |
|
Deltamac Taiwan Co Ltd
TWO:6144
|
Taiwan | NT$54.15 Million |
|
Dolphin International Bhd
KLSE:5265
|
Malaysia | RM15.11 Million |
|
Emerson Radio Corporation
NYSE MKT:MSN
|
USA | $1.41 Million |
Liability Composition Analysis (2007–2023)
This chart breaks down Acticor Biotech SAS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Acticor Biotech SAS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Acticor Biotech SAS (2007–2023)
The table below shows the annual total liabilities of Acticor Biotech SAS from 2007 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €15.03 Million | -1.03% |
| 2022-12-31 | €15.19 Million | +121.27% |
| 2021-12-31 | €6.86 Million | -26.23% |
| 2020-12-31 | €9.30 Million | +46.07% |
| 2019-12-31 | €6.37 Million | +23.22% |
| 2018-12-31 | €5.17 Million | -15.53% |
| 2017-12-31 | €6.12 Million | -48.80% |
| 2016-12-31 | €11.95 Million | -7.77% |
| 2015-12-31 | €12.96 Million | +0.09% |
| 2014-12-31 | €12.94 Million | -3.83% |
| 2013-12-31 | €13.46 Million | +23.92% |
| 2012-12-31 | €10.86 Million | +78.42% |
| 2011-12-31 | €6.09 Million | +21.09% |
| 2010-12-31 | €5.03 Million | +39.07% |
| 2009-12-31 | €3.62 Million | +69.32% |
| 2008-12-31 | €2.13 Million | +210.77% |
| 2007-12-31 | €687.00K | -- |